Evidence map›Paper›PMID 39085998›Full record

ArticleJournal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society2025

Optical Coherence Tomography Angiography Retinal Imaging Associations With Burden of Small Vessel Disease and Amyloid Positivity in the Brain.

Camilo Bermudez, Timothy G Lesnick, Swati S More, Vijay K Ramanan, David S Knopman, Alejandro A Rabinstein, Petrice M Cogswell, Clifford R Jack, Prashanthi Vemuri, Ronald C Petersen and 2 more

Abstract read
In one paragraph

Article in Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Retinal imaging for cerebrovascular risk stratification: evidence, limitations, and practical thresholds for the ophthalmologist.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Cerebral Amyloid Deposition WithHuman brain mapping · 2025
    Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Camilo BermudezDepartment of Neurology (CB, VKR, DSK, AAR, RCP, JG-R, JJC), Mayo Clinic, Rochester, Minnesota; Center for Drug Design (SSM), College of Pharmacy, University of Minnesota, Minneapolis, Minnesota; Departments of Radiology (PMC, CRJ, PV) and Ophthalmology (JJC), Mayo Clinic, Rochester, Minnesota; and Department of Quantitative Health Sciences (TGL), Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-9461-5094
Timothy G Lesnick
Swati S More
Vijay K Ramanan
David S Knopman
Alejandro A Rabinstein
Petrice M Cogswell
Clifford R Jack
Prashanthi Vemuri
Ronald C Petersen
Jonathan Graff-Radford
John J Chen

Funding

SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
Rochester Epidemiology ProjectR01AG034676 · NIA · MAYO CLINIC ROCHESTER · PI ROCCA, WALTER A, ST SAUVER, JENNIFER LYNN · 2010 to 2019
$9.5M
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkersR37AG011378 · NIA · MAYO CLINIC ROCHESTER · PI CLIFFORD R. JACK · 2018 to 2026
$6.8M
"What is N?" Towards operationalizing neurodegeneration in Alzheimer's and related dementiasRF1AG069052 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, MIELKE, MICHELLE M · 2021 to 2021
$2.4M
Minnesota Partnership for Biotechnology and Medical Genomics Grant Retinal Hyperspectral Imaging: A Tool for Early Detection of Alzheimer's DiseaseNIA NIH HHS R01 AG034676NIA NIH HHS R37 AG011378NIA NIH HHS RF1 AG069052NIA NIH HHS U01 AG006786University of Minnesota MNP #18.06
6 · The paper itself

Abstract

backgroundAlzheimer disease (AD) and other dementias are associated with vascular changes and amyloid deposition, which may be reflected as density changes in the retinal capillaries. These changes may can be directly visualized and quantified with optical coherence tomography angiography (OCTA), making OCTA a potential noninvasive preclinical biomarker of small vessel disease and amyloid positivity. Our objective was to investigate the feasibility of retinal imaging metrics as noninvasive biomarkers of small vessel disease and amyloid positivity in the brain.

methodsWe investigated associations between OCTA and neuroimaging and cognitive metrics in 41 participants without dementia from the Mayo Clinic Study of Aging and Alzheimer's Disease Research Center. OCTA metrics included superficial, deep, and full retina capillary density of the fovea, parafovea, and macula as well as the area of the foveal avascular zone (FAZ). Neuroimaging metrics included a high burden of white matter hyperintensity (WMH), presence of cerebral microbleeds (CMB), lacunar infarcts, and amyloid positivity as evidenced on positron emission tomography (PET), whereas cognitive metrics included mini-mental status examination (MMSE) score. We performed generalized estimating equations to account for measurements in each eye while controlling for age and sex to estimate associations between OCTA metrics and neuroimaging and cognitive scores.

resultsAssociations between OCTA and neuroimaging metrics were restricted to the fovea. OCTA showed decreased capillary density with high burden of WMH in both the superficial ( P = 0.003), deep ( P = 0.004), and full retina ( P = 0.01) in the fovea but not the parafovea or whole macula. Similarly, participants with amyloid PET positivity had significantly decreased capillary density in the superficial fovea ( P = 0.027) and deep fovea ( P = 0.03) but higher density in the superficial parafovea ( P = 0.038). Participants with amyloid PET positivity also had a significantly larger FAZ ( P = 0.031), whereas in those with high WMH burden the difference did not reach statistical significance ( P = 0.075). There was also a positive association between MMSE and capillary density of the full retina within the fovea ( P = 0.037) and in the superficial parafovea ( P = 0.046). No associations were found between OCTA metrics and presence of CMB or presence of lacunar infarcts.

conclusionsThe associations of lower foveal capillary density with cerebral WMH and amyloid positivity suggest that further research is warranted to evaluate for shared mechanisms of disease between small vessel disease and AD pathologies.

Indexed as

BrainCerebral Small Vessel DiseasesFluorescein AngiographyRetinal VesselsTomography, Optical CoherenceAgedAged, 80 and overAlzheimer DiseaseFemaleHumansMaleMiddle AgedPositron-Emission Tomography

Identifiers

PMID39085998
PMCPMC12367338

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.